Tackling Resistance to Cancer Immunotherapy: What Do We Know?

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2020 Sep 11

PMID 32911646

Citations 8

Authors

Soehartati A Gondhowiardjo

Handoko

Vito Filbert Jayalie

Riyan Apriantoni

Andreas Ronald Barata

Fajar Senoaji

Igaa Jayanthi Wulan Utami

Ferdinand Maubere

Endang Nuryadi

Angela Giselvania

Affiliations

Soon will be listed here.

Abstract

Cancer treatment has evolved tremendously in the last few decades. Immunotherapy has been considered to be the forth pillar in cancer treatment in addition to conventional surgery, radiotherapy, and chemotherapy. Though immunotherapy has resulted in impressive response, it is generally limited to a small subset of patients. Understanding the mechanisms of resistance toward cancer immunotherapy may shed new light to counter that resistance. In this review, we highlighted and summarized two major hurdles (recognition and attack) of cancer elimination by the immune system. The mechanisms of failure of some available immunotherapy strategies were also described. Moreover, the significance role of immune compartment for various established cancer treatments were also elucidated in this review. Then, the mechanisms of combinatorial treatment of various conventional cancer treatment with immunotherapy were discussed. Finally, a strategy to improve immune cancer killing by characterizing cancer immune landscape, then devising treatment based on that cancer immune landscape was put forward.

Citing Articles

Cold Tumour Phenotype Explained Through Whole Genome Sequencing in Clinical Nasopharyngeal Cancer: A Preliminary Study.

Handoko , Adham M, Rachmadi L, Wibowo H, Gondhowiardjo S Immunotargets Ther. 2024; 13:173-182.

PMID: 38524775 PMC: 10959245. DOI: 10.2147/ITT.S452117.

Wang Y, Yan K, Guo Y, Lu Y, Su H, Li H Front Immunol. 2023; 13:1085491.

PMID: 36700205 PMC: 9868931. DOI: 10.3389/fimmu.2022.1085491.

Deciphering Driver of Nasopharyngeal Cancer Development.

Handoko , Louisa M, Permata T, Gondhowiardjo S Oncol Rev. 2022; 16:10654.

PMID: 36531162 PMC: 9756839. DOI: 10.3389/or.2022.10654.

Lessons learned from immunological characterization of nanomaterials at the Nanotechnology Characterization Laboratory.

Dobrovolskaia M Front Immunol. 2022; 13:984252.

PMID: 36304452 PMC: 9592561. DOI: 10.3389/fimmu.2022.984252.

Nanomedicines for Overcoming Cancer Drug Resistance.

Hu T, Gong H, Xu J, Huang Y, Wu F, He Z Pharmaceutics. 2022; 14(8).

PMID: 36015232 PMC: 9412887. DOI: 10.3390/pharmaceutics14081606.

References

Goans R, Waselenko J . Medical management of radiological casualties. Health Phys. 2005; 89(5):505-12. DOI: 10.1097/01.hp.0000172144.94491.84. View

McGoverne I, Dunn J, Batham J, Tu W, Chrisp J, Rao S . Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response. BMC Immunol. 2020; 21(1):22. PMC: 7175524. DOI: 10.1186/s12865-020-00353-0. View

McLaughlin M, Patin E, Pedersen M, Wilkins A, Dillon M, Melcher A . Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020; 20(4):203-217. DOI: 10.1038/s41568-020-0246-1. View

Du X, Tang F, Liu M, Su J, Zhang Y, Wu W . A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res. 2018; 28(4):416-432. PMC: 5939050. DOI: 10.1038/s41422-018-0011-0. View

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot D, Adam J . Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014; 20(11):1301-9. DOI: 10.1038/nm.3708. View

Zebertavage L, Alice A, Crittenden M, Gough M . Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity. Sci Rep. 2020; 10(1):7376. PMC: 7193601. DOI: 10.1038/s41598-020-64408-3. View

Gonzalez-Rodriguez A, Villa-Alvarez M, Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez S . NK Cells in the Treatment of Hematological Malignancies. J Clin Med. 2019; 8(10). PMC: 6832953. DOI: 10.3390/jcm8101557. View

Davar D, Wang H, Chauvin J, Pagliano O, Fourcade J, Ka M . Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol. 2018; :JCO1800632. PMC: 6286160. DOI: 10.1200/JCO.18.00632. View

Orhan A, Vogelsang R, Andersen M, Madsen M, Holmich E, Raskov H . The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis. Eur J Cancer. 2020; 132:71-84. DOI: 10.1016/j.ejca.2020.03.013. View

10.

Muller W . Getting leukocytes to the site of inflammation. Vet Pathol. 2013; 50(1):7-22. PMC: 3628536. DOI: 10.1177/0300985812469883. View

11.

Kruger S, Ilmer M, Kobold S, Cadilha B, Endres S, Ormanns S . Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res. 2019; 38(1):268. PMC: 6585101. DOI: 10.1186/s13046-019-1266-0. View

12.

Yarchoan M, Johnson 3rd B, Lutz E, Laheru D, Jaffee E . Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017; 17(4):209-222. PMC: 5575801. DOI: 10.1038/nrc.2016.154. View

13.

van der Woude L, Gorris M, Halilovic A, Figdor C, de Vries I . Migrating into the Tumor: a Roadmap for T Cells. Trends Cancer. 2017; 3(11):797-808. DOI: 10.1016/j.trecan.2017.09.006. View

14.

Schaue D, McBride W . T lymphocytes and normal tissue responses to radiation. Front Oncol. 2012; 2:119. PMC: 3445965. DOI: 10.3389/fonc.2012.00119. View

15.

Yang X, Zhang X, Fu M, Weichselbaum R, Gajewski T, Guo Y . Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell. 2014; 25(1):37-48. PMC: 3927846. DOI: 10.1016/j.ccr.2013.12.004. View

16.

Rock K, Reits E, Neefjes J . Present Yourself! By MHC Class I and MHC Class II Molecules. Trends Immunol. 2016; 37(11):724-737. PMC: 5159193. DOI: 10.1016/j.it.2016.08.010. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala A, Shen S . Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 2013; 21(1):79-91. PMC: 3857631. DOI: 10.1038/cdd.2013.75. View

19.

Oh S, Lee J, Kwack K, Choi S . Natural Killer Cell Therapy: A New Treatment Paradigm for Solid Tumors. Cancers (Basel). 2019; 11(10). PMC: 6826624. DOI: 10.3390/cancers11101534. View

20.

Vakkila J, Lotze M . Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004; 4(8):641-8. DOI: 10.1038/nri1415. View